- Home
- GCI vs CTMX Comparison
GCI vs CTMX Comparison
Compare GCI & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCI
- CTMX
- Stock Information
- Founded
- GCI 1997
- CTMX 2008
- Country
- GCI United States
- CTMX United States
- Employees
- GCI N/A
- CTMX N/A
- Industry
- GCI Newspapers/Magazines
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- GCI Consumer Discretionary
- CTMX Health Care
- Exchange
- GCI Nasdaq
- CTMX Nasdaq
- Market Cap
- GCI 621.7M
- CTMX 596.2M
- IPO Year
- GCI N/A
- CTMX 2015
- Fundamental
- Price
- GCI $4.55
- CTMX $3.85
- Analyst Decision
- GCI Buy
- CTMX Strong Buy
- Analyst Count
- GCI 3
- CTMX 6
- Target Price
- GCI $5.70
- CTMX $6.50
- AVG Volume (30 Days)
- GCI 3.1M
- CTMX 3.8M
- Earning Date
- GCI 10-30-2025
- CTMX 11-06-2025
- Dividend Yield
- GCI N/A
- CTMX N/A
- EPS Growth
- GCI N/A
- CTMX 50.22
- EPS
- GCI 0.59
- CTMX 0.24
- Revenue
- GCI $2,338,505,000.00
- CTMX $113,631,000.00
- Revenue This Year
- GCI N/A
- CTMX N/A
- Revenue Next Year
- GCI N/A
- CTMX N/A
- P/E Ratio
- GCI $7.65
- CTMX $16.20
- Revenue Growth
- GCI N/A
- CTMX N/A
- 52 Week Low
- GCI $2.55
- CTMX $0.40
- 52 Week High
- GCI $5.69
- CTMX $4.62
- Technical
- Relative Strength Index (RSI)
- GCI 49.42
- CTMX 55.41
- Support Level
- GCI $4.96
- CTMX $3.42
- Resistance Level
- GCI $5.29
- CTMX $4.45
- Average True Range (ATR)
- GCI 0.34
- CTMX 0.35
- MACD
- GCI -0.04
- CTMX -0.05
- Stochastic Oscillator
- GCI 44.02
- CTMX 42.13
About GCI Gannett Co. Inc.
Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S. The group operates in three segments, Domestic Gannett Media, Newsquest, and Digital Marketing Solutions. The majority of revenue is from the Domestic Gannett Media segment. The company's brands include USA TODAY and more than 250 daily newspapers as well as digital marketing services companies, including ReachLocal, WordStream, and others. The company produces more than 350 annual events, such as themed expos. The company also operates in the U.K. through the U.K. media company Newsquest, providing more than 150 local media brands.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.